Terrence Bradley

1.1k total citations · 1 hit paper
50 papers, 483 citations indexed

About

Terrence Bradley is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Terrence Bradley has authored 50 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Hematology, 24 papers in Genetics and 12 papers in Molecular Biology. Recurrent topics in Terrence Bradley's work include Acute Myeloid Leukemia Research (37 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Terrence Bradley is often cited by papers focused on Acute Myeloid Leukemia Research (37 papers), Chronic Myeloid Leukemia Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (12 papers). Terrence Bradley collaborates with scholars based in United States, United Kingdom and Poland. Terrence Bradley's co-authors include Justin M. Watts, Naval Daver, Gary J. Schiller, David A. Sallman, James McCloskey, Alexander E. Perl, Mark R. Litzow, Jessica K. Altman, Ramón V. Tiu and Mark J. Levis and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Terrence Bradley

43 papers receiving 480 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

2022 123 citations Naval Daver, Alexander E. Perl et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Terrence Bradley United States	11	348	274	96	81	71	50	483
Yasmin Abaza United States	11	261 0.8×	174 0.6×	87 0.9×	67 0.8×	60 0.8×	54	391
Juergen Krauter Germany	7	332 1.0×	213 0.8×	90 0.9×	69 0.9×	55 0.8×	20	424
Ahmad Antar Lebanon	6	269 0.8×	135 0.5×	55 0.6×	51 0.6×	50 0.7×	13	333
Hayley Ma United States	7	245 0.7×	201 0.7×	91 0.9×	93 1.1×	60 0.8×	10	415
Álex Bataller United States	10	208 0.6×	131 0.5×	93 1.0×	90 1.1×	46 0.6×	51	319
Jing-Zhou Hou United States	2	418 1.2×	268 1.0×	115 1.2×	99 1.2×	28 0.4×	3	498
Hollie Devine United States	7	343 1.0×	257 0.9×	50 0.5×	146 1.8×	131 1.8×	9	524
Christina Rautenberg Germany	14	482 1.4×	164 0.6×	114 1.2×	69 0.9×	67 0.9×	37	533
Yazan F. Madanat United States	9	258 0.7×	126 0.5×	114 1.2×	66 0.8×	41 0.6×	71	333
Barbara Spitzer United States	10	267 0.8×	273 1.0×	72 0.8×	63 0.8×	62 0.9×	39	475

Countries citing papers authored by Terrence Bradley

Since Specialization

Citations

This map shows the geographic impact of Terrence Bradley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Terrence Bradley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Terrence Bradley more than expected).

Fields of papers citing papers by Terrence Bradley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Terrence Bradley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Terrence Bradley. The network helps show where Terrence Bradley may publish in the future.

Co-authorship network of co-authors of Terrence Bradley

This figure shows the co-authorship network connecting the top 25 collaborators of Terrence Bradley. A scholar is included among the top collaborators of Terrence Bradley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Terrence Bradley. Terrence Bradley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Watts, Justin M., Maurizio Affer, Jennifer R. Chapman, et al.. (2025). Functional cure with single agent olutasidenib in relapsed IDH1/NPM1 co-mutated AML. npj Precision Oncology. 9(1). 211–211.

Vachhani, Pankit, Raajit K. Rampal, Terrence Bradley, et al.. (2024). POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib. Blood. 144(Supplement 1). 1808.2–1808.2. 1 indexed citations

Sekeres, Mikkael A., Hetty E. Carraway, Richard M. Stone, et al.. (2024). A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results. Blood. 144(Supplement 1). 1821–1821. 1 indexed citations

Mascarenhas, John, Salman Otoukesh, Terrence Bradley, et al.. (2024). Trial Update from IMproveMF, an Ongoing, Open-Label, Dose-Escalation and -Expansion, Phase 1/1B Trial to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Novel Combination of Imetelstat with Ruxolitinib in Patients with Intermediate-1, Intermediate-2, or High-Risk Myelofibrosis (MF). Blood. 144(Supplement 1). 998–998. 1 indexed citations

Itonaga, Hidehiro, Adnan K. Mookhtiar, Sarah Greenblatt, et al.. (2024). Tyrosine phosphorylation of CARM1 promotes its enzymatic activity and alters its target specificity. Nature Communications. 15(1). 3415–3415. 2 indexed citations

Kuykendall, Andrew, Terrence Bradley, Rami S. Komrokji, et al.. (2023). PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF. HemaSphere. 7(S3). e906057e–e906057e. 1 indexed citations

Daver, Naval, Alexander E. Perl, Joseph Maly, et al.. (2022). Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology. 40(35). 4048–4059. 123 indexed citations breakdown →

Stanchina, Michele, et al.. (2022). Profile of Glasdegib for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML): Evidence to Date. Cancer Management and Research. Volume 14. 2267–2272. 11 indexed citations

Alencar, Alvaro J., et al.. (2022). The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products. Leukemia Research Reports. 18. 100355–100355. 1 indexed citations

10.

Daver, Naval, Paresh Vyas, Suman Kambhampati, et al.. (2022). AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results. Clinical Lymphoma Myeloma & Leukemia. 22. S253–S254. 5 indexed citations

11.

Totiger, Tulasigeri M., Evan R. Roberts, Maurizio Affer, et al.. (2022). Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14). npj Precision Oncology. 6(1). 73–73. 12 indexed citations

12.

Santos, Helena G. Dos, Deukwoo Kwon, Terrence Bradley, et al.. (2021). Clinical Responsiveness to All-trans Retinoic Acid Is Potentiated by LSD1 Inhibition and Associated with a Quiescent Transcriptome in Myeloid Malignancies. Clinical Cancer Research. 27(7). 1893–1903. 32 indexed citations

13.

Singh, Abhay, Swapna Thota, Terrence Bradley, et al.. (2021). Outcomes of Adult Acute Myeloid Leukemia Treated With Gemtuzumab-Ozogamicin: Cue To Optimized Chemotherapy Backbone. Clinical Lymphoma Myeloma & Leukemia. 21(9). 613–620. 1 indexed citations

14.

Totiger, Tulasigeri M., Terrence Bradley, Francesco Maura, et al.. (2021). Combination Venetoclax and Selinexor Effective in Relapsed/Refractory Multiple Myeloma with Translocation t(11;14). Blood. 138(Supplement 1). 2270–2270. 2 indexed citations

15.

Raja, Mohammed, Yoichiro Natori, José F. Camargo, et al.. (2020). Discordance Between Radiologic Findings and Molecular Testing in Patients With Underlying Hematologic Malignancy and Coronavirus Disease 2019. Open Forum Infectious Diseases. 7(9). ofaa372–ofaa372. 1 indexed citations

16.

Bradley, Terrence, et al.. (2020). Spontaneous remission of acute myeloid leukemia with NF1 alteration. Leukemia Research Reports. 13. 100204–100204. 6 indexed citations

17.

Moyo, Tamara K., Justin M. Watts, Barry Skikne, et al.. (2019). Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition. Blood. 134(Supplement_1). 4236–4236. 10 indexed citations

18.

Bradley, Terrence, Matthew Salzberg, Basem Azab, et al.. (2017). Splenectomy in a Severe Case of Acquired Factor X Deficiency Secondary to Amyloidosis: Case Discussion and Review of the Literature. Blood. 130. 4885–4885. 1 indexed citations

19.

Bradley, Terrence, et al.. (2012). Tumor Lysis Syndrome in Small Cell Cancer of Prostate. CHEST Journal. 142(4). 626A–626A. 3 indexed citations

20.

Smith, G M, M A Forbes, John A. Cooper, et al.. (2008). Prognostic indicators for the development of AIDS in HIV antibody positive haemophiliac patients: results of a three-year longitudinal study. Clinical & Laboratory Haematology. 13(2). 115–125.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact